Cargando…

Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?

Detalles Bibliográficos
Autores principales:	Liu, Jun-Li, Gao, Zu-hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443942/ https://www.ncbi.nlm.nih.gov/pubmed/30876763 http://dx.doi.org/10.1016/j.ebiom.2019.03.012

Ejemplares similares

Head Over Hepatocytes for FGF21
por: Potthoff, Matthew J., et al.
Publicado: (2014)

Role of Fibroblast Growth Factor 21 in Biology of Glucagon
por: Berglund, Eric D., et al.
Publicado: (2013)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020)

Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
por: Kouno, Tetsuya, et al.
Publicado: (2022)

Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression
por: Trzaskalski, Natasha A., et al.
Publicado: (2023)

GLP-2 cures the gut – What about the liver?
por: Pakarinen, Mikko P.
Publicado: (2019)

Propofol Improved Glucose Tolerance Associated with Increased FGF-21 and GLP-1 Production in Male Sprague-Dawley Rats
por: Wu, Chih-Cheng, et al.
Publicado: (2020)

From fibroblast cells to cardiomyocytes: direct lineage reprogramming
por: Yang, Lei
Publicado: (2011)

Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?
por: Zuurbier, Coert J.
Publicado: (2020)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Is endogenous GLP-1 a major influence on the orbitofrontal cortex?
por: May, Aaron A., et al.
Publicado: (2015)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Direct conversion of porcine primary fibroblasts into hepatocyte-like cells
por: Fráguas-Eggenschwiler, Mariane, et al.
Publicado: (2021)

Fibroblast Growth Factor 21 Suppresses Adipogenesis in Pig Intramuscular Fat Cells
por: Wang, Yongliang, et al.
Publicado: (2015)

Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats
por: Brinker, Emily J., et al.
Publicado: (2023)

Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
por: D'Alessio, David A.
Publicado: (2010)

Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKA(y) Mice
por: Nonogaki, Katsunori, et al.
Publicado: (2014)

How Does Pioglitazone Prevent Progression of Impaired Glucose Tolerance to Diabetes?
por: Genuth, Saul M.
Publicado: (2013)

Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
por: Solomon, Thomas P.J., et al.
Publicado: (2022)

Suppression of Cutibacterium acnes-Mediated Inflammatory Reactions by Fibroblast Growth Factor 21 in Skin
por: Yu, Ying, et al.
Publicado: (2022)

Rapid production of engineered human primary hepatocyte/fibroblast sheets
por: Sakai, Yusuke, et al.
Publicado: (2015)

Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3
por: Taddeo, Evan P., et al.
Publicado: (2017)

GLP-1–Based Therapies and the Exocrine Pancreas: More Light, or Just More Heat?
por: Gale, Edwin A.M.
Publicado: (2012)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

Fibroblast growth factor 21 has no direct role in regulating fertility in female mice
por: Singhal, Garima, et al.
Publicado: (2016)

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation
por: Lee, Yun Sok, et al.
Publicado: (2019)

Phenylpropanoid Glycerol Glucosides Attenuate Glucose Production in Hepatocytes
por: Murray, Anne F., et al.
Publicado: (2019)

An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes
por: Rosario, Wilfredo, et al.
Publicado: (2015)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Does the COVID-19 Pandemic Spell the End for the Direct Ophthalmoscope?
por: Shih, Kendrick C., et al.
Publicado: (2020)

Somatic MIWI2 Hinders Direct Lineage Reprogramming From Fibroblast to Hepatocyte
por: Shi, Xiaojie, et al.
Publicado: (2019)

SIRT3 Directs Carbon Traffic in Muscle to Promote Glucose Control
por: Huynh, Frank K., et al.
Publicado: (2015)

Liver-brain axis with alcohol: Role of fibroblast growth factor 21 (FGF21)
por: Zhang, Ke, et al.
Publicado: (2023)

Dietary Protein Regulates Female Estrous Cyclicity Partially via Fibroblast Growth Factor 21
por: Cao, Yaxue, et al.
Publicado: (2023)

Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?
por: Nicholls, Stephen J., et al.
Publicado: (2018)

Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts
por: Matsumoto-Taniura, N, et al.
Publicado: (1999)

Fibroblast growth factor 21 in heart failure
por: Tucker, William, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mnmpb5l24t1204s85mp7u9ti13